OptimizeRx Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results.

OptimizeRx Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results.

Benzinga7minutes ago

Expert Ratings For OptimizeRx

OptimizeRx (NASDAQ:OPRX) has been analyzed by 5 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.The table below offers a condensed view of their re

Benzinga21:00

OptimizeRx Is Maintained at Buy by Stifel

OptimizeRx Is Maintained at Buy by Stifel

Dow Jones20:01

Stifel Maintains Buy on OptimizeRx, Maintains $13 Price Target

Stifel analyst David Grossman maintains OptimizeRx with a Buy and maintains $13 price target.

Analyst Upgrades19:51

OptimizeRx Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/15/2024 13.04% Stifel $13 → $13 Maintains Buy 04/16/2024 30.43% JMP Securities → $15 Reiterates Market

Benzinga19:51

Stifel Nicolaus Reaffirms Their Buy Rating on OptimizeRx (OPRX)

TipRanks18:56